NIH Grant to Aid Gene Therapy Research on Eyes

Article

Gainesville, FL-Scientists seeking to use gene therapy to reverse a form of inherited blindness have won a $9.8-million grant from the National Institutes of Health (NIH).

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
Related Content
First Patient With Multiple Myeloma Dosed in EsoBiotec's Trial for In Vivo CAR-T ESO-T01

First Patient With Multiple Myeloma Dosed in EsoBiotec's Trial for In Vivo CAR-T ESO-T01

Noah Stansfield
January 9th 2025
Article

According to EsoBiotec, this is the first time a patient has been treated with an in vivo BCMA-directed CAR-T therapy in a clinical trial.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

Around the Helix: Cell and Gene Therapy Company Updates – January 8, 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 8, 2025

Noah Stansfield
January 8th 2025
Article

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona

The Promise of Cell Therapy Approaches in Epilepsy

Marco Meglio
December 17th 2024
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Jonathan Parker, MD, PhD.

Heather Lau, MD, MS

Ultragenyx Puts BLA for MPSIII Gene Therapy UX111 in Front of FDA

Noah Stansfield
January 7th 2025
Article

Ultragenyx is seeking accelerated approval for the BLA based on the use of CSF heparan sulfate data from the phase 1/2/3 Transpher A clinical trial.

Arbor Biotechnologies’ CRISPR-Based Gene Editing Therapy ABO-101 Cleared for US Trial in Primary Hyperoxaluria Type 1

Arbor Biotechnologies’ CRISPR-Based Gene Editing Therapy ABO-101 Cleared for US Trial in Primary Hyperoxaluria Type 1

Noah Stansfield
January 6th 2025
Article

Arbor noted it has designed redePHine, a phase 1/2 clinical trial (NCT identifier pending) that will evaluate ABO-101 in adults and children with PH1.

© 2025 MJH Life Sciences

All rights reserved.